![\"\"](\"https:\/\/evertise.net\/wp-content\/uploads\/2025\/11\/doseology.png\")
<\/p>\n<\/p>\n
Kelowna, BC \u2013 <\/strong>November 13, 2025<\/strong> \u2013 Doseology Sciences Inc.<\/strong> (CSE: <\/a>MOOD<\/strong><\/a> | PINK: <\/a>DOSEF<\/strong><\/a> | FSE: <\/a>VU70<\/strong><\/a>) (\u201cDoseology\u201d or the \u201cCompany\u201d), an innovator in precision-formulated oral stimulants, is pleased to announce that its wholly owned Florida subsidiary, Doseology USA Inc., has executed a confidential manufacturing agreement with a leading North American production partner.<\/p>\n This milestone represents a step in Doseology\u2019s operational evolution\u2014establishing the commercial infrastructure, manufacturing capacity, and regulatory foundation required to support the Company\u2019s transition from development of its oral stimulant pouches to full market readiness.<\/p>\n \u201cThis is much more than a manufacturing agreement, it\u2019s a defining moment as it enables Doseology to move from R&D to commercial deployment,\u201d said Tim Corkum, President & COO of Doseology. \u201cThrough Doseology USA Inc., we\u2019ve secured an American partner that delivers the scale, quality, and integrity we require as we prepare to enter the oral stimulant pouch market.\u201d<\/p>\n Doseology\u2019s leadership conducted on-site reviews, operational assessments, and compliance audits across numerous facilities throughout the United States and Canada.<\/p>\n After rigorous evaluation, the Company selected a partner recognized for:<\/p>\n \u201cOur diligence process was deliberate and comprehensive,\u201d added Corkum. \u201cWe wanted an American manufacturing partnership that reflects our core values\u2014integrity, quality, and accountability. As we enter the market, this ensures Doseology\u2019s products are built on a foundation of trusted North American craftsmanship and scientific precision.\u201d<\/p>\n The signing of this manufacturing agreement by Doseology USA Inc. marks a key inflection point in Doseology\u2019s investment and commercialization cycle, demonstrating that the Company has now established the operational backbone to execute its strategy and deliver measurable progress in the oral stimulant pouch market.<\/p>\n \u201cThis step validates our readiness to scale,\u201d said Corkum. \u201cWe\u2019ve secured the right partner, the right structure, and the right systems to move confidently into the next stage of our growth. For shareholders, this milestone signals tangible execution and a disciplined pathway toward value creation.\u201d<\/p>\n \u201cThis agreement represents a pivotal step in Doseology\u2019s ability to commercialize efficiently and responsibly,\u201d added Patrick Sills, Strategic Commercialization Advisor to Doseology. \u201cHaving worked closely with global category leaders such as Swedish Match<\/em>, the parent company behind ZYN<\/em>, I\u2019ve seen firsthand how disciplined manufacturing, compliance, and scalability form the bedrock of long-term success. Doseology\u2019s approach\u2014combining science-driven product development with thoroughly vetted North American infrastructure\u2014built on the same strategic foundation that defined today\u2019s market leading oral stimulant brands. This partnership validates the Company\u2019s commitment to execution, quality, and shareholder value.\u201d<\/p>\n Led by executives with deep experience in regulated Big Tobacco, CPG, Nutraceuticals, and Corporate Finance, Doseology continues to build a North American infrastructure network designed to support innovation, compliance, and performance at scale.<\/p>\n The establishment of Doseology USA Inc. further strengthens the Company\u2019s operational presence in the United States and underscores its commitment to American-made production integrity, sustainable growth, and long-term shareholder value.<\/p>\n About Doseology Sciences Inc. <\/strong>(CSE: <\/a>MOOD<\/strong><\/a> | PINK: <\/a>DOSEF<\/strong><\/a> | FSE: <\/a>VU70<\/strong><\/a>)<\/p>\n Doseology is a biotech innovation company, engineering precision\u2011formulated oral stimulants that are designed to optimize energy, focus, and cognitive performance. Through rigorous scientific research and advanced delivery technologies, we’re pioneering next\u2011gen performance solutions designed to empower peak performance.<\/p>\n On behalf of the Board of Directors, For more information, please contact the Company at: Forward Looking Statements<\/strong><\/p>\n This press release contains statements that constitute \u201cforward\u2010looking information\u201d within the meaning of applicable securities laws. Forward\u2010looking information is often identified by the words \u201cmay,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect\u201d or similar expressions. Readers are cautioned that forward\u2010looking information is not based on historical facts but instead reflects the Company\u2019s management\u2019s expectations, estimates or projections concerning the business of the Company\u2019s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward\u2010looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward\u2010looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company\u2019s prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward\u2010looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward\u2010looking information except as otherwise required by applicable law. For more information, investors should review the Company\u2019s filings which are available on SEDAR+<\/a>.<\/p>\n No securities regulatory authority has either approved or disapproved of the contents of this press release.<\/p>\n","protected":false},"excerpt":{"rendered":" Kelowna, BC \u2013 November 13, 2025 \u2013 Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70) (\u201cDoseology\u201d or the \u201cCompany\u201d), an innovator in precision-formulated oral stimulants, is pleased to announce that its wholly owned Florida subsidiary, Doseology USA Inc., has executed a confidential manufacturing agreement with a leading North American production partner. This [\u2026] Continue Reading Extensive Diligence Across North America<\/strong><\/h3>\n
\n
\n
A Defining Milestone for Shareholders<\/strong><\/h3>\n
Building for Market Leadership<\/strong><\/h3>\n
\n<\/strong>Chris Jackson
\nCEO
\nDoseology Sciences Inc.<\/p>\n
\nEmail:<\/strong> hello@doseology.com<\/a>
\nWebsite:<\/strong> www.doseology.com<\/a>
\nPhone: <\/strong>604.908.3095<\/p>\n